Brain Immunoactivation in Drug-Naive Patients with First Episode Schizophrenia
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
KaSP is a multimodal observational study with the goal of clarifying underlying mechanisms that cause psychotic disorders, such as schizophrenia. Participants with psychotic symptoms are recruited early after first contact with health care, within 4 weeks of starting anti-psychotic medication, and are compared to controls without psychiatric diagnoses on several measures.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
⁃ For FEP:
• Diagnosis as assessed using DSM-IV of one of the following: schizophrenia, schizophreniform psychosis, psychosis not otherwise specified (NOS), brief psychosis, schizoaffective syndrome, delusional disorder
• First exposure to anti-psychotic medication less than 4 weeks prior to inclusion
Locations
Other Locations
Sweden
SLSO Psykiatri Stockholm in collaboration w Karolinska Institutet
RECRUITING
Stockholm
Contact Information
Primary
Carl M Sellgren, MD, PhD
carl.sellgren@ki.se
+46 702127287
Backup
Lena Lundberg
lena.lundberg.2@ki.se
+46725223907
Time Frame
Start Date: 2011-01-25
Estimated Completion Date: 2032-12-31
Participants
Target number of participants: 200
Treatments
First Episode Psychosis (FEP)
Diagnosis of psychotic disorder according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV), where anti-psychotic medication was initiated less than four weeks prior to inclusion.
Healthy Control (HC)
Age and sex matched individuals
Related Therapeutic Areas
Sponsors
Collaborators: Centre for Psychiatry Research, Region Stockholm, Sweden
Leads: Karolinska Institutet